Anti-CagA antibodies seroprevalence of Helicobacter pylori and its relationship with epidemiological factors in Santa Fe;Seroprevalencia de anticuerpos anti-CagA de Helicobacter pylori y su relacion con factores epidemiologicos en Santa Fe

Acta Gastroenterologica Latinoamericana

Volumn 34, Issue 1, 2004, Pages 16-20

  Jiménez, Felix ^a   Demaría, José Luis ^a   Ahumada, Carlos ^a   Nagel, Alicia ^a   Baroni, María Rosa ^b   Giugni, María Cristina ^b   Méndez, Emilse ^a  

^a Hospital Jose M Cullen   (Argentina)

^b UNIVERSIDAD NACIONAL DEL LITORAL   (Argentina)

Author keywords

Antibodies; CagA; Epidemiology; Helicobacter pylori

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; CAGA PROTEIN, HELICOBACTER PYLORI; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; AGED; ARGENTINA; ARTICLE; BLOOD; EPIDEMIOLOGY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; PREDICTION AND FORECASTING; RISK FACTOR;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; ARGENTINA; BACTERIAL PROTEINS; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES;

EID: 4444317287     PISSN: 03009033     EISSN: 03009033     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Jiménez F, Demaria J, Ahumada C et al Evaluación de las técnicas de diagnóstico para la detección de Helicobacter pylori en mucosa gástrica. I Congreso International de Infecrología y Microbiología Clinica, Buenos Aires, 1997.
2. Gisbert J. Revisión crítica de los métodos diagnósticos de infección por Helibacter pylori. Gastroenterología y Hepatología 2000,23:135-143.
3. Figueiredo C, Quint W, Nouhan N et al Assessment of Helicobacter pylori vacA and cagA Genotypes and Host Serological Response. J Clin Microbiol 2001;39:1339-1344.
4. Brouter N, Marais A, Lamouliatte H, Mascarel A, Samoyeau R, Salamon R, and Megraud F, cagA Status and Eradication Treatment Outcome of Anti-Helicobacter pylori Triple Therapies in Patients with Nonulcer Dyspepsia. J Clin Microbiol 2001;39:1319-1322.
5. Leuak R. Production of a cytotoxin by Helicobacter pylori. Rev Infect Dis 1995;13:686.
6. Censini S, Lange C, Xiang Z et al cag a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc. Natl Acad. Sci. USA. 1996;93:14648-14653.
7. Kato S, Sugiyama M Kudo et al CagA antibodies in Japanese children with nodular gastritis or peptic ulcer desease. J Clin Microbiol 2000;38:68-70.
8. Ikenoue T, Macda S, Ogura K et al Determination of Helicobacter pylori Virulence by Simple Gene Analysis of the cag Pathogenicity Island. Clin and Diag Labor Immun 2001;8:181-186.
9. Blaser M, Perez-Perez G, Kleanthous H et al Infection with Helicobacter pylori strains possessing cag A is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer res 1995;55:2111-2115.
10. Kulpers E, Perez-Perez GI, Meuwissen S, and Blasser M, Helicobacter pylori and atrophic gastritis: importance of the cagA status. J Natl Cancer Inst 1995;87:1777-1780.
11. Beales I, Crabtree J, Scunes D et al Antibodies to CagA protein are associated with gastric atrophy in Helicobacter pylori infection. Eur. J Gastroenterol Hepatol 1996;8:645-649.
12. Atherton J, Cao P, Peek R et al Mosaicism in vacuola-ting cytotoxin alleles of Helicobacter pylori. Asociation of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem 270:17771-17777.
13. Bonvicini F, Baldini L, Pretolani S et al Anti-CagA antibodies are associated with artrophic gastritis in a population a: high gastric cancer risk a morphometric study by computerized image analysis. Ital. J Gastroenterol Hepatol 1997;29:409-414.
14. Lamarque D, Gilbert T, Roudot-Thoraval F et al Seroprevalence of eight Helicobacter pylori antigens among 182 patients with peptic ulcer, MALT gastric lymphoma or non ulcer dyspepsia. Higher rate of seroreactivity against CagA and 35-kDaantigens in patients with peptic ulcer originating from Europe and Africa. Eur. J Gastroenterol Hepatol 1999;11:721-726.
15. Kuipers E. Perez-Perez G, Meuwissen S et al Helicobacter pylori and atrophic gastritis: importance of cagA status. J Natl Cancer Inst 1995;87:1777-1780.
16. Walpole R y Myers R Probabilidad y estadistica. 1995;8:355-366.
17. Norman G y Streiner L, Bioestadística 1996;4:150-154.
18. Aliman D, Practical Statistics for Medical Research. 1991;12:325-358.
19. Pérez Valmaseda T, Gisbert J, y Pajares García J. Diferencias geográficas y papel del gen cagA en las enfermedades gastroduode-nales asociadas a la infección por Helicobacter pylori.
20. Olmos A, Rios H, Higa R. Prevalence of Helicobacter pylori Infection in Argentina. J Clin Gastroenterol 2000;31:33-37.
21. Pest P, Corti R, Pedrana R et al Seroprevalencia de la infección por Helicobacter pylori en la República Argentina. Acta Gastroent Latinoamer 1999;29:297-305.
22. Santolaria S, Barrios Y, Benito R et al Helicobacter pylori y factores inmunogenéticos del huésped: relevancia de los alelos HLADQAI-•0102 y •0301 en la úlcera péptica. Gastroenterol Hepatol 2001;24:117-121.
23. Rudi J, Kolb C, Maiwald M, Zuna I et al Serum antibodies against Helicobacter pylori proteins VacA and CagA are associated with increased risk for gastric adenocarcinoma. Dig Dis Sci 1997;42:1652-1659.
24. Parsonnet J, Friedman G, Orentreich N et al Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997;40:297-301.
25. Maaroos H, Vorobjova T, Sipponen P et al An 18 year follow-up study of chronic gastritis and Helicobacter pylori association of CagA positivity with development of atrophy and activity of gastritis. Scand. J Gastroenterol 1999;34:864-869.
26. Wong B, Lam S, Ching C et al Seroprevalence of cytotoxin-associated gene A positive Helicobacter pylori strains in Changle, an area with very high prevalence of gastric cancer in south China. Aliment. Pharmacol, Ther. 1999;13:1295-1302.
27. World Health Organization. Incidence mortality and survival databases, WHO cancer Mortality databank. 1996.